Breaking News Instant updates and real-time market news.

MCRB

Seres Therapeutics

$4.80

0.26 (5.73%)

07:05
01/03/19
01/03
07:05
01/03/19
07:05

Seres Therapeutics initiates SER-287 Phase 2B ECO-RESET clinical study

Seres Therapeutics announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis. Seres has received $40M in milestone payments associated with this study start from Nestle Health Science. The SER-287 Phase 2B ECO-RESET study has been designed as a pivotal trial. The company recently obtained feedback from the FDA indicating that results from this study, in conjunction with data from a second pivotal study, could enable a SER-287 Biologics License Application. The Phase 2B study is a three-arm placebo-controlled trial of approximately 200 patients with active mild-to-moderate ulcerative colitis. Two groups of patients will receive different doses of SER-287, both following pretreatment with a short course of oral vancomycin. A third study arm will receive placebo. The study's primary endpoint will evaluate clinical remission measured after 10 weeks of SER-287 administration. Endoscopic improvement will be measured as a secondary efficacy measure.

  • 18

    May

MCRB Seres Therapeutics
$4.80

0.26 (5.73%)

10/22/18
CHDN
10/22/18
INITIATION
Target $15
CHDN
Buy
Seres Therapeutics initiated with a Buy at Chardan
Chardan initiated Seres Therapeutics with a Buy and $15 price target.
08/03/18
08/03/18
DOWNGRADE
Target $6

Underperform
Seres Therapeutics downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Seres Therapeutics to Underperform from Neutral and cut its price target to $6 from $13. Analyst Tazeen Ahmad said management has not provided a timeline yet for the ECOSPOR III study of '109 and pushed out his expected launch date to 2021 from 2020. Ahmad believes Seres' microbiome-based pipeline could yield new treatment options for many diseases but notes the landscape is becoming increasingly competitive.
08/03/18
BOFA
08/03/18
DOWNGRADE
BOFA
Underperform
Seres Therapeutics downgraded to Underperform from Neutral at BofA/Merrill

TODAY'S FREE FLY STORIES

07:02
11/20/19
11/20
07:02
11/20/19
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 11/15 MBA…

BR

Broadridge

$122.16

1.55 (1.29%)

07:02
11/20/19
11/20
07:02
11/20/19
07:02
Hot Stocks
Broadridge acquires ClearStructure Financial Technology, terms not disclosed »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$56.48

-1.14 (-1.98%)

07:00
11/20/19
11/20
07:00
11/20/19
07:00
Hot Stocks
Bristol-Myers: Statistically significant benefit not reached in CheckMate -915 »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:00
11/20/19
11/20
07:00
11/20/19
07:00
General news
European stock markets sold off, »

European stock markets…

PAGS

PagSeguro Digital

$36.81

-1.04 (-2.75%)

06:59
11/20/19
11/20
06:59
11/20/19
06:59
Recommendations
PagSeguro Digital analyst commentary  »

PagSeguro Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

NWBI

Northwest Bancshares

$16.76

(0.00%)

06:58
11/20/19
11/20
06:58
11/20/19
06:58
Initiation
Northwest Bancshares initiated  »

Northwest Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALX

Calix

$7.71

0.06 (0.78%)

06:57
11/20/19
11/20
06:57
11/20/19
06:57
Conference/Events
Calix management to meet with Northland »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

FTNT

Fortinet

$105.04

1.24 (1.19%)

06:56
11/20/19
11/20
06:56
11/20/19
06:56
Recommendations
Fortinet analyst commentary  »

Fortinet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

, NEX

NexTier Oilfield

$4.67

-0.07 (-1.48%)

06:56
11/20/19
11/20
06:56
11/20/19
06:56
Downgrade
RPC, Inc., NexTier Oilfield rating change  »

Citi downgrades RPC to…

RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

NEX

NexTier Oilfield

$4.67

-0.07 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAPL

CrossAmerica

$17.38

0.26 (1.52%)

06:55
11/20/19
11/20
06:55
11/20/19
06:55
Hot Stocks
CrossAmerica comments on sale of company interests by Alimentation Couche-Tard »

CrossAmerica and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CREE

Cree

$48.01

0.44 (0.92%)

06:55
11/20/19
11/20
06:55
11/20/19
06:55
Conference/Events
Cree to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BRT

BRT Apartments

$17.17

0.2 (1.18%)

06:54
11/20/19
11/20
06:54
11/20/19
06:54
Conference/Events
BRT Apartments management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

NEX

NexTier Oilfield

$4.67

-0.07 (-1.48%)

, RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

06:54
11/20/19
11/20
06:54
11/20/19
06:54
Initiation
NexTier Oilfield, RPC, Inc. initiated  »

NexTier Oilfield…

NEX

NexTier Oilfield

$4.67

-0.07 (-1.48%)

RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSMT

Osmotica Pharmaceuticals

$4.96

0.34 (7.36%)

06:53
11/20/19
11/20
06:53
11/20/19
06:53
Hot Stocks
Vertical Pharmaceuticals: FDA accepts NDA for RVL-1201 »

Vertical Pharmaceuticals,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHR

Braemar Hotels & Resorts

$9.67

(0.00%)

06:51
11/20/19
11/20
06:51
11/20/19
06:51
Conference/Events
Braemar Hotels & Resorts management to meet with DA Davidson »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LODE

Comstock Mining

$0.08

0.0027 (3.41%)

06:51
11/20/19
11/20
06:51
11/20/19
06:51
Hot Stocks
Comstock Mining granted approval for mercury remediation plant in Nevada »

Comstock Mining received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$60.66

1.12 (1.88%)

06:50
11/20/19
11/20
06:50
11/20/19
06:50
Recommendations
TJX analyst commentary  »

TJX price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GCI

Gannett

$0.00

(0.00%)

06:50
11/20/19
11/20
06:50
11/20/19
06:50
Hot Stocks
Gannett announces senior leadership for newly combined company »

Gannett announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$89.02

0.31 (0.35%)

, AGN

Allergan

$185.25

0.72 (0.39%)

06:48
11/20/19
11/20
06:48
11/20/19
06:48
Recommendations
AbbVie, Allergan analyst commentary  »

AbbVie price target…

ABBV

AbbVie

$89.02

0.31 (0.35%)

AGN

Allergan

$185.25

0.72 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AFIN

American Finance Trust

$15.03

-0.07 (-0.46%)

06:47
11/20/19
11/20
06:47
11/20/19
06:47
Conference/Events
American Finance Trust afinmanagement to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 12

    Dec

MRK

Merck

$84.64

0.52 (0.62%)

06:47
11/20/19
11/20
06:47
11/20/19
06:47
Hot Stocks
Merck: EC approves two new regimens of KEYTRUDA »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 10

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ADDYY

Adidas

$0.00

(0.00%)

06:45
11/20/19
11/20
06:45
11/20/19
06:45
Conference/Events
Adidas management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

BILI

Bilibili

$15.74

-0.65 (-3.97%)

06:45
11/20/19
11/20
06:45
11/20/19
06:45
Recommendations
Bilibili analyst commentary  »

Bilibili price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:45
11/20/19
11/20
06:45
11/20/19
06:45
General news
Breaking General news story  »

Week of 11/15 MBA…

QD

Qudian

$5.63

-0.295 (-4.98%)

06:44
11/20/19
11/20
06:44
11/20/19
06:44
Recommendations
Qudian analyst commentary  »

Qudian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.